tiprankstipranks
Trending News
More News >
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Hong Kong Market

Compare Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) vs. Competitors

Compare
2 Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Top Analysts' Price Target
Smart Score
Follow
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
HK$5.19
HK$18.40B
16.96
49.34%
HUTCHMED (China)
HK$21.18
HK$21.02B
5.75
14.64%
4 Buy
0 Hold
0 Sell
Strong Buy
Shanghai Fosun Pharmaceutical (Group) Co
HK$19.63
HK$75.54B
15.78
60.40%
3 Buy
1 Hold
0 Sell
Strong Buy
China Resources Pharmaceutical Group Ltd.
HK$4.61
HK$28.71B
9.44
-12.05%
CanSino Biologics, Inc. Class H
HK$44.94
HK$14.16B
-57.70
26.89%
1 Buy
0 Hold
0 Sell
Moderate Buy

Performance Comparison

Ticker
Company Name
Price
Change
% Change
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
5.66
2.21
64.06%
HK:0013
HUTCHMED (China)
23.96
3.46
16.88%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
20.98
8.37
66.34%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.60
-0.49
-9.63%
HK:1558
HK:6185
CanSino Biologics, Inc. Class H
35.72
7.37
26.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts